Savara Inc. (NASDAQ:SVRA) Receives $8.86 Consensus Price Target from Brokerages

Savara Inc. (NASDAQ:SVRA) has received an average recommendation of “Moderate Buy” from the nine research firms that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, six have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $8.8571.

A number of brokerages have recently commented on SVRA. UBS Group set a $10.00 price objective on Savara in a research report on Tuesday, December 23rd. Guggenheim reiterated a “buy” rating on shares of Savara in a research report on Tuesday, December 23rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Savara in a research note on Thursday, January 22nd. Wells Fargo & Company lifted their price target on Savara from $7.00 to $9.00 and gave the company an “overweight” rating in a report on Thursday, December 18th. Finally, Wall Street Zen raised shares of Savara from a “sell” rating to a “hold” rating in a research note on Saturday, November 15th.

Savara Trading Down 4.0%

Shares of SVRA opened at $5.27 on Monday. The stock has a fifty day moving average of $5.73 and a two-hundred day moving average of $4.86. The company has a debt-to-equity ratio of 0.32, a quick ratio of 7.65 and a current ratio of 7.65. The company has a market capitalization of $1.07 billion, a PE ratio of -9.94 and a beta of 0.31. Savara has a fifty-two week low of $1.89 and a fifty-two week high of $7.01.

Hedge Funds Weigh In On Savara

Institutional investors and hedge funds have recently bought and sold shares of the stock. Mirae Asset Global Investments Co. Ltd. increased its holdings in Savara by 48.0% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 9,887 shares of the company’s stock valued at $60,000 after purchasing an additional 3,205 shares in the last quarter. Russell Investments Group Ltd. boosted its position in shares of Savara by 930.5% in the third quarter. Russell Investments Group Ltd. now owns 10,480 shares of the company’s stock worth $37,000 after buying an additional 9,463 shares during the period. Xponance LLC purchased a new stake in shares of Savara in the fourth quarter worth about $66,000. CIBC Bancorp USA Inc. acquired a new stake in shares of Savara in the third quarter valued at about $44,000. Finally, Prudential Financial Inc. acquired a new stake in shares of Savara in the second quarter valued at about $30,000. Institutional investors and hedge funds own 87.93% of the company’s stock.

About Savara

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.